Interview: Monika Rühl – CEO, economiesuisse, Switzerland
For the eighth year in a row the World Economic Forum has ranked Switzerland first in both global competitiveness and in innovation; economiesuisse CEO Monika Rühl discusses the main issues…
Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufacturing and commercialization of innovative therapies. Patients in more than 90 countries benefit from Biogen Idec’s significant products that address diseases such as multiple sclerosis (MS), lymphoma and rheumatoid arthritis. In 2008, Biogen Idec’s total revenues grew 29 percent over 2007 to $4.1 billion. Biogen Idec is headquartered in Cambridge, Massachusetts, with international headquarters in Zug, Switzerland. They have additional offices in the US, Canada, Australia, Japan and throughout Europe. Biogen Idec has a direct commercial presence in 29 markets, a network of distribution partners in more than 70 additional markets and operations in several new markets, including Central/Eastern Europe, Brazil, China and India.
Contact Info
Biogen Idec Switzerland AG
Zählerweg 6
CH 6300 Zug
Switzerland
Phone: +41 41 728 7444
Fax: +41 41 728 7440
www.biogenidec.ch
International Headquarters
Biogen Idec International GmbH
Landis & Gyr-Strasse 3
CH 6300 Zug
Switzerland
Phone: +41 41 39 21700
Fax: +41 41 39 21710
www.biogenidec-international.com
For the eighth year in a row the World Economic Forum has ranked Switzerland first in both global competitiveness and in innovation; economiesuisse CEO Monika Rühl discusses the main issues…
Michelle Lock describes the positive challenges that come with expanding a biopharmaceutical business that possesses a well-regarded pipeline, and that continuously launches products across the Alpine region. She highlights the…
An increasing number of pharma MNCs are looking towards Switzerland for their European base. Despite high costs compared to elsewhere in Europe, Switzerland’s infrastructure, location, and R&D ecosystem make it…
An increasing number of pharma MNCs are looking towards Switzerland for their European base. Despite high costs compared to elsewhere in Europe, Switzerland’s infrastructure, location, and R&D ecosystem make it…
Dr. André T. Dahinden, General Manager of Amgen Switzerland, talks about their four cutting-edge products that will help drive future growth, reveals how being innovative includes partnering with payers for…
Michael Cobas Meyer of Eli Lilly Switzerland reveals how these are very exciting times for the company, particularly given an extremely rich pipeline in the areas of diabetes, oncology and…
Walter P. Hölzle, president of vips, discusses the current priorities of the association, the importance of innovation, and the challenges of the current pricing system. While growth is close to…
Kari Sarvanto introduces Primex, an innovative fast-growing company spearheading a new pharmaceutical business model, strongly focusing on anesthesiology. He talks about entrepreneurship, innovation and new ways of achieving success in…
Gaelle Meaude, operations director of Thea Switzerland, talks about building an effective sales and marketing team over the last few years; why the Swiss preservative-free eye care market remains particularly…
Nicolas Hug reveals how UCB´s new facility in Bulle, Switzerland, is one of the largest microbial derived pharmaceuticals plants in Europe; how the key challenge for manufacturers today is to…
As the home market, Switzerland and Roche’s Swiss pharma operations play an important and pioneering role within Roche’s global organization, with early patient access to innovation and new commercial models…
Heike Behn, reveals how her number one priority at Nordic Pharma Switzerland, the group’s’newest affiliate, is to develop their rheumatology business, building on their gynecology platform; how the speed with…
See our Cookie Privacy Policy Here